anti-PD-L1/TGFbeta bispecific antibody (GigaGen)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-PD-L1/TGFbeta bispecific antibody (GigaGen)

Drug Alias Namedual PD-L1 checkpoint inhibitor/TGF beta modulator (GigaGen)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionProgrammed death-ligand 1 blockersTGF-β pathway modulators

TargetsTransforming growth factor betaProgrammed death-ligand 1

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesGigaGen Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesGigaGen Inc

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A